Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.14129
Abstract: The development of an anti‐FVIII inhibitor is the most serious complication of haemophilia A occurring in up to 30% of severe haemophilic patients. The current management of haemophilia A with inhibitor uses bypassing agents (BPA)… read more here.
Keywords: bleeding episodes; patients anti; prevention bleeding; anti fviii ... See more keywords
Epitope Dependent Augmentation of the Immune Response in Hemophilia Α Mice Immunized with Factor VIII/Antibody Immune Complexes
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-127436
Abstract: Introduction: The immune response to factor VIII (fVIII) is a CD4+ T cell dependent process initiated by fVIII recognition and processing by antigen presenting cells. The C1 and C2 domains have been proposed as the… read more here.
Keywords: mice immunized; fviii; board; immune response ... See more keywords
Non-Human Glycans Can Regulate Anti-FVIII Antibody Formation in Mice.
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2020009210
Abstract: Recombinant Factor VIII (FVIII) products represent a life-saving intervention for patients with hemophilia A. However, patients can develop antibodies against FVIII that prevent FVIII function and directly increase morbidity and mortality. The development of anti-FVIII… read more here.
Keywords: non human; antibody; fviii; derived fviii ... See more keywords
Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?
Sign Up to like & getrecommendations! Published in 2022 at "Blood advances"
DOI: 10.1182/bloodadvances.2021004909
Abstract: The most common complication in hemophilia A (HA) treatment, affecting 25-30% of severe HA patients, is the development of alloimmune inhibitors that foreclose the ability of infused factor VIII (FVIII) to participate in coagulation. Inhibitors… read more here.
Keywords: anti fviii; fviii; bdd fviii; hemophilia ... See more keywords
Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.692157
Abstract: The most challenging complication associated with Factor VIII (FVIII) replacement therapy is the development of neutralizing anti-drug antibodies, or inhibitors, which occur in 23-35% of severe (FVIII level read more here.
Keywords: factor; anti fviii; rfviiifc; factor viii ... See more keywords